US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Antibody Technologies: market research reports

Monoclonal antibodies (mAbs) are large protein molecules produced by white blood cells that seek out and destroy harmful foreign substances. Monoclonal antibodies are finding wide application in many areas of medicine and biologic science. These antibodies have begun to replace conventional antibodies in blood banking and are used in the identification of organisms in the bacteriology laboratory.
Monoclonal antibodies have also been extensively used in radioimmunoassay to measure serum levels of various substances. They have very useful in quantitating types of WBCs and subgroups of lymphocytes. They are also used in the diagnosis of leukemia. More recently, monoclonal antibodies have been used in the treatment of malignancies. They have been used to treat transplant rejection episodes, purge bone marrow of tumor cells in bone marrow transplants, and remove mature T cells that cause GVH disease in bone marrow transplants.

There are several types of monoclonal antibodies on the market and in development. Most of the monoclonal antibodies on the market are whole antibodies, while some are fragments of antibodies. There are also variable fragment monoclonal antibodies and bispecific monoclonal antibodies.

RSS Feeds

Antibody Technologies market research reports and industry analysis

< prev 1    3  4  5  6  7  8  9  10  
Analytical Tool - Apoptosis in Oncology
3/25/2014 | published by: BioSeeker Group AB
... of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product ...  |  read more...
$11,625.00
Analytical Tool - Antibodies and Peptides in Oncology
3/25/2014 | published by: BioSeeker Group AB
... business development in the antibody and peptide cancer drug competitive landscape. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide ...  |  read more...
$22,312.50
Analytical Tool - Cancer Immunotherapy
3/25/2014 | published by: BioSeeker Group AB
... is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays ...  |  read more...
$20,437.50
Analytical Tool - Cancer Therapeutic Antibodies
3/25/2014 | published by: BioSeeker Group AB
... of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product ...  |  read more...
$14,810.00
Antibodies in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... for the second wave in the lucrative field of therapeutic antibodies. There are today 313 companies plus partners developing 671 antibody drugs in 1619 developmental projects in cancer. In addition, there are 8 suspended drugs ...  |  read more...
$5,622.50
Antibodies in Oncology: Drug Pathway Analyzer 2014
3/25/2014 | published by: BioSeeker Group AB
... intracellular signaling pathways for the treatment of more than 107 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 264 drug targets that are included ...  |  read more...
$5,622.50
Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014
3/12/2014 | published by: La Merie Publishing
... recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of March 2014. Marketed antibodies are attractive for companies to create next generation variants and ...  |  read more...
$1,523.00
Investigation Report on China Adalimumab Market, 2010-2018
3/6/2014 | published by: China Research and Intelligence Co., Ltd.
... BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and developed by BASF Knoll (BASF Pharma) and, ultimately, manufactured and marketed by Abbott Laboratories after the acquisition of ...  |  read more...
$1,800.00
Competitor Analysis: EGF-R Antibodies –Biosimilars and Biosuperiors
3/4/2014 | published by: La Merie Publishing
... to treat solid tumors as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access ...  |  read more...
$347.00
Global Antibody Drug Conjugate Market Outlook 2018
3/1/2014 | published by: RNCOS
... and antibody proved a setback. But, the past few years have witnessed ADCs make a glorious comeback. This can be attributed to the significant advancements that have been made in the field of linker technology ...  |  read more...
$1,200.00
Competitor Analysis: TNF Antibodies –Biosimilars and Biosuperiors
2/28/2014 | published by: La Merie Publishing
... in the field of recombinant antibodies targeting tumor necrosis factor (TNF) alpha or its receptor used to treat various inflammatory and autoimmune diseases as of March 2014. Purchase of the downloadable pdf report includes a ...  |  read more...
$555.00
Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors
2/19/2014 | published by: La Merie Publishing
... field of recombinant antibodies targeting Her2 for treatment of Her2 positive breast and gastric cancer as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the ...  |  read more...
$416.00
Bispecific Antibodies: Clinical Trial Tracker
2/13/2014 | published by: Roots Analysis
... different epitopes concurrently. Various technology platforms have been used for bsAbs production over the years. These platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. Different binding ...  |  read more...
$799.00
Competitor Analysis: VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors
2/13/2014 | published by: La Merie Publishing
... recombinant antibodies targeting vascular endothelial growth factor (VEGF) used to treat various cancers and ophthalmic diseases as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of ...  |  read more...
$401.00
Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors
2/10/2014 | published by: La Merie Publishing
... for treatment of B-cell mediated malignancies and rheumatoid arthritis as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the ...  |  read more...
$401.00
Antibody Drug Conjugates: Contract Manufacturing Market, 2014-2024
2/5/2014 | published by: Roots Analysis
... antibody. However, the practical challenge of manufacturing such complex and highly toxic molecules is huge. The multi-component aspect of ADCs deems it necessary to have both biologic and high-potency facilities. Despite the fact that this ...  |  read more...
$1,899.00
Antibody Drug Conjugates: Technologies and Global Markets
2/1/2014 | published by: BCC Research
... annual growth rate (CAGR) of 48.1%. This report provides: An overview of the global market for ADCs as a part of the pharmaceutical industry that is looking for innovative technologies. Analyses of global market trends, ...  |  read more...
$6,650.00
Monoclonal Antibodies Partnering Terms and Agreements
2/1/2014 | published by: Current Partnering
... obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest ...  |  read more...
$2,995.00
Antibody Deals and Alliances of 2013
2/1/2014 | published by: Current Partnering
... during 2013. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. ...  |  read more...
$1,495.00
Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis
1/19/2014 | published by: La Merie Publishing
... more than 90 companies. The report analyzes established and new antibody-drug conjugate (ADC) technologies, business activities and opportunities and assesses more than 100 ADC development and research programs. The commercial value of ADC technologies, ADC ...  |  read more...
$2,873.00
Competitor Analysis: Immunocytokines
1/3/2014 | published by: La Merie Publishing
... work with engineering of the cytokine payloads promises new molecular entities with better tolerability and safety. The present Competitive Intelligence report about  Immunocytokines provides a competitor evaluation in the field of recombinant fusion proteins of ...  |  read more...
$334.00
Biobetters Trends
1/1/2014 | published by: Global Industry Analysts
... The primary characteristics targeted by these applicants include extended half-life in human body, improved bioavailability, lower immunogenicity, higher purity, and fewer side-effects. These molecules contain the same active ingredients such as antibodies to target the ...  |  read more...
$950.00
Global Protein Therapeutics Market Outlook 2018
1/1/2014 | published by: RNCOS
... clinical methods to treat a wide spectrum of diseases ranging from cancer to metabolic disorders. The market holds tremendous potential for future growth and it is estimated that by the end of 2018, it may ...  |  read more...
$1,800.00
Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth
12/15/2013 | published by: GBI Research
... Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth”. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic ...  |  read more...
$3,500.00
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
12/15/2013 | published by: GBI Research
... and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” Gastric and esophageal cancers are two orphan cancers of the gastrointestinal tract. They are often diagnosed at advanced, incurable ...  |  read more...
$3,500.00
< prev 1    3  4  5  6  7  8  9  10  
 
Our Clients